Download Document

SUBMISSION OF CURRICULUM VITAE (CV)
TO RESEARCH ETHICS COMMITTEES AND NHS R&D OFFICES
Guidance for applicants
Your CV needs to demonstrate that you are qualified by education, training and experience
to conduct the research.
A standard template for an investigator CV is set out below. This template would be suitable
for submission of CVs by:



Chief Investigators (for submission with main REC application)
Local Principal Investigators (for submission with the Site-Specific Information Form
to RECs and NHS R&D offices)
Academic supervisors (for submission with student applications).
The template is issued as guidance and is not intended to be prescriptive. Use of the
template is not a requirement for a valid application.
The NRES Standard Operating Procedures state that CVs should be a maximum of 2 pages.
This is also guidance and is not an absolute requirement.
It is important that experience relevant to the specific research project is fully summarised,
but the overall document should be kept concise. It is not necessary to provide a complete
record of the applicant’s professional and academic background. In particular, CVs should
not include lengthy lists of publications.
This template is recommended by NRES and the NHS R&D Forum for applications
both for ethical review and R&D approval.
Page 1 of 4
CV for LCTU
CURRICULUM VITAE
Name:
William Greenhalf
Present appointment: (Job title, department, and organisation.)
Senior Lecturer in Molecular Oncology, Division of Surgery and Oncology, The University of
Liverpool
Address: (Full work address.)
Division of Molecular and Clinical Cancer Medicine, University of Liverpool,
Duncan Building, Daulby Street, Liverpool L69 3GA.
Telephone number:
Email address:
01513361227
[email protected]
Qualifications:
BSc(Hons) Biochemistry and Molecular Biology, 2.1; UMIST 1986
PhD “Plasmid stability in Saccharomyces cerevisiae; UMIST 1990
Professional registration: (Name of body, registration number and date of registration.)
Previous and other appointments: (Include previous appointments in the last 5 years and
other current appointments.)
1990-1993
Visiting Lecturer at the São Paulo State university (UNESP), Brazil.
1993-1994
Research assistant to Dr. G. Morris at NEWI, Clwyd, UK
1995-1996
Post doctoral researcher in the department of Core Drug Development at Ciba-Geigy,
Basel.
1996-1997
Post doctoral researcher in the department of Oncology at Novartis, Basel.
1997-2006
Lecturer in Molecular Onclology, Division of Surgery and Oncology, The University
of Liverpool
2006-2011
Senior Lecturer in Molecular Onclology, Division of Surgery and Oncology, The
University of Liverpool
2011-date
Reader in Molecular Onclology, Molecular and Clinical Cancer Medicine, The
University of Liverpool and Director of Liverpool GCLP Facility
Research experience: (Summary of research experience, including the extent of your
involvement. Refer to any specific clinical or research experience)
My research is at the interface between clinical and basic science, I have been the lead scientist of the
European Registry of Hereditary Pancreatitis and Familial Pancreatitis (EUROPAC) since 1997.
I sit on various trial steering committee. Including the EUROPAC2 trial (anti-oxidants and magnesium
for the treatment of pancreatitis). The Vandetanib in Pancreatic Cancer (VIP) Trial and The European
Study Group for Pancreatic Cancer (ESPAC, trials of adjuvant therapy in pancreatic cancer) Tissue
group.
I sit on the Cancer Research UK Quality Assurance and Translational Science (QATS) Steering
Committee, the Confederation of UK Biobanks UK Working Group for Harmonisation, Standardisation
and Benchmarking of Biobanks and on the BSG United Kingdom and Ireland Pancreatic Guidelines
Development Group which is in the process of seeking NICE accreditation. I am also on the Scientific
Advisory Panel for the nascent Dutch Pancreatic Biobank. I am on the editorial board of the World
Journal of Gastroenterology and Nature Scientific Reports.
In Liverpool I am part of the NIHR Pancreatic Biomedical Research Unit (PBRU) Steering Group and I
am part of the Cancer Research UK Liverpool Cancer Research Centre. I also sit on the Faculty of
Medicine Genetic Modification Advisory Committee.
I have grant funding from Cancer Research UK the NIHR, PCRF, PCUK and the European Union.
Including recent funding from the NIHR via i4i for isolation of circulating tumour cells and two
European Union Framework 7 grants looking at biomarkers and therapeutic targets for pancreatic
cancer.
I am Operational Director of the Liverpool GCLP facility.
Page 2 of 4
CV for LCTU
Research training: (Details of any relevant training in the design or conduct of research, for
example in the Clinical Trials Regulations, Good Clinical Practice, consent or other training
appropriate to non-clinical research. Give the date of the training.)
I attend regular GCP training courses. Including the UKCRN course “GCP and the EU
Directive for experienced Staff”. The MHRA seminar “Statutory GCP inspections of clinical
laboratories” and The Global Biobank Meeting in London in 2012. I hosted the Biobanking
and Bioinformatics (B3i) meeting in Liverpool in 2012 (sponsored by the CRUK via the
ECMC)
Relevant publications:
1.
Shaw VE, Lane B, Jenkinson C, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from
benign pancreatic disease. Mol Cancer 2014; 13: 114.
2.
Nicholson J, Greenhalf W, Jackson R, et al. Incidence of Post- ERCP Pancreatitis from Direct Pancreatic Juice
Collection in Hereditary Pancreatitis and Familial Pancreatic Cancer before and after the Introduction of Prophylactic
Pancreatic Stents and Rectal Diclofenac Pancreas 2014;
3.
Middleton G, Silcocks P, Cox T, et al. A Phase III Randomised Trial Of Chemo-Immunotherapy Comprising
Gemcitabine And Capecitabine (GemCap) With Or Without Telomerase Peptide Vaccine GV1001 In Patients With Locally
Advanced Or Metastatic Pancreatic Cancer: Final Results Of The TeloVacTrial. Lancet Oncol 2014; In Press.
4.
Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from
gemcitabine in patients from the ESPAC-3 trial. Journal of the National Cancer Institute 2014; 106(1): djt347.
5.
Tonack S, Jenkinson C, Cox T, et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of
obstructive jaundice on their performance. British journal of cancer 2013; 108(9): 1846-53.
6.
Rizzato C, Campa D, Pezzilli R, et al. ABO blood groups and pancreatic cancer risk and survival: Results from the
PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep 2013.
7.
Rachakonda PS, Bauer AS, Xie H, et al. Somatic mutations in exocrine pancreatic tumors: association with patient
survival. PLoS ONE 2013; 8(4): e60870.
8.
Kolamunnage-Dona R, Vitone L, Greenhalf W, Henderson R, Williamson PR. A multistate modelling approach for
pancreatic cancer development in genetically high-risk families. J R Stat Soc C-Appl 2013; 62(2): 201-12.
9.
Huang W, Booth DM, Cane MC, et al. Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca2+dependent mitochondrial dysfunction and acute pancreatitis. Gut 2013.
10.
Campa D, Rizzato C, Capurso G, et al. Genetic susceptibility to pancreatic cancer and its functional
characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis 2013; 45(2): 95-9.
11.
Whitcomb DC, LaRusch J, Krasinskas AM, ..Greenhalf et al. Common genetic variants in the CLDN2 and PRSS1PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet 2012;44(12):1349-54.
12.
Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application
to treatment. Nat Rev Gastroenterol Hepatol 2012;9:435-44.
13.
Bauer AS, Keller A, Costello E, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by
measurement of microRNA abundance in blood and tissue. PLoS ONE 2012;7:e34151.
14.
Greenhalf W, Thomas A. Combination therapy for the treatment of pancreatic cancer. Anticancer Agents Med
Chem 2011;11:418-26.
15.
Tweedle EM, Khattak I, Ang CW, Nedjadi T, Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, Grabsch
H, Mueller W, Myint S, Clark P, Wong H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E. Low molecular weight heat
shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 2010;59:1501-10.
16.
Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK. PALB2
mutations in European familial pancreatic cancer families. Clin Genet 2010;78:490-4.
17.
Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, Middleton GW. Current status of GV1001
and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010;9:1007-16.
18.
Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, Gress TM,
Michl P. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 2010;59:1101-10.
19.
Grocock CJ, Rebours V, Delhaye MN, Andren-Sandberg A, Weiss FU, Mountford R, Harcus MJ, Niemczyck E, Vitone
LJ, Dodd S, Jorgensen MT, Ammann RW, Schaffalitzky de Muckadell O, Butler JV, Burgess P, Kerr B, Charnley R, Sutton R,
Raraty MG, Deviere J, Whitcomb DC, Neoptolemos JP, Levy P, Lerch MM, Greenhalf W. The variable phenotype of the
p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut 2010;59:357-63.
20.
Earl J, Greenhalf W. Single-nucleotide polymorphism (SNP) analysis to associate cancer risk. Methods Mol Biol
2010;576:171-96.
21.
Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP.
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 2010;102:577-82.
22.
Milne RL, Greenhalf W, Murta-Nascimento C, Real FX, Malats N. The Inherited Genetic Component of Sporadic
Pancreatic Adenocarcinoma. Pancreatology 2009;9:206-214.
23.
Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of High-Risk Families for Pancreatic Cancer.
Pancreatology 2009;9:215-222
24.
Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced
pancreatic cancer. Expert Rev Gastroenterol Hepatol 2008;2:673-96.
25.
Greenhalf W, Malats N, Nilsson M, Bartsch D, Neoptolemos J. International Registries of Families at High Risk of
Pancreatic Cancer. Pancreatology 2008;8:558-565.
26.
Slater E, Amrillaeva V, Fendrich V, Bartsch D, Earl J, Vitone LJ, Neoptolemos JP, Greenhalf W. Palladin mutation
causes familial pancreatic cancer: absence in European families. PLoS Med 2007;4:e164.
Page 3 of 4
CV for LCTU
27.
Burkitt M, Magee C, O'Connor D, Campbell F, Cornford P, Greenhalf W. Potentiation of chemotherapeutics by the
Hsp90 antagonist geldanamycin requires a steady serum condition. Mol Carcinog 2007;46:466-475.
28.
Vitone LJ, Greenhalf W, McFaul CD, Ghaneh P, Neoptolemos JP. The inherited genetics of pancreatic cancer and
prospects for secondary screening. Best Pract Res Clin Gastroenterol 2006;20:253-83.
29.
McFaul C, Greenhalf W, Earl J, Howes N, Neoptolemos J, Kress R, Sina-Frey M, Rieder H, Hahn SA, Bartsch D.
Anticipation in familial pancreatic cancer. Gut 2006;55:252-258.
30.
Latchford A, Greenhalf W, Vitone LJ, Neoptolemos JP, Lancaster GA, Phillips RK. Peutz-Jeghers syndrome and
screening for pancreatic cancer. Br J Surg 2006;93:1446-55.
31.
Greenhalf W, Neoptolemos JP. Increasing survival rates of patients with pancreatic cancer by earlier
identification. Nat Clin Pract Oncol 2006;3:346-7.
32.
Greenhalf W. An unfavourable prognosis for pancreatic cancer indicates fields of opportunity. Gut 2006;55:15335.
33.
Earl J, Yan L, Vitone LJ, Risk J, Kemp SJ, McFaul C, Neoptolemos JP, Greenhalf W, Kress R, Sina-Frey M, Hahn SA,
Rieder H, Bartsch DK. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers
Prev 2006;15:1948-55.
Signature:
Date:
09-02-2015
Page 4 of 4
CV for LCTU